Top Page
Concord Healthcare Group Co., Ltd. Class H
(2453)
Concord Healthcare Group Co., Ltd. Class H (2453) vs. iShares MSCI Hong Kong ETF (EWH)
Concord Healthcare Group Co., Ltd. Class H Business Overview & Revenue Model
Concord Healthcare Group Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 370.22M | 388.31M | 538.65M | 472.17M | 470.50M | 166.32M |
| Gross Profit | -32.36M | -67.25M | -65.09M | -197.46M | -92.76M | -17.27M |
| EBITDA | -153.23M | -194.46M | -172.58M | -355.51M | -356.26M | -229.19M |
| Net Income | -437.94M | -443.22M | -373.09M | -541.40M | -816.59M | -583.26M |
Balance Sheet | ||||||
| Total Assets | 5.77B | 5.91B | 5.24B | 6.08B | 6.66B | 5.90B |
| Cash, Cash Equivalents and Short-Term Investments | 170.03M | 337.12M | 49.23M | 136.06M | 136.09M | 424.83M |
| Total Debt | 3.23B | 3.21B | 2.64B | 2.85B | 2.48B | 2.21B |
| Total Liabilities | 3.95B | 4.01B | 3.37B | 3.84B | 8.08B | 6.52B |
| Stockholders Equity | 1.54B | 1.65B | 1.60B | 1.69B | -1.56B | -678.14M |
Cash Flow | ||||||
| Free Cash Flow | 100.47M | -500.12M | 18.11M | -175.66M | -584.24M | -915.43M |
| Operating Cash Flow | -67.57M | -185.96M | 201.85M | -93.64M | 45.87M | -51.85M |
| Investing Cash Flow | -229.03M | -668.09M | -182.34M | -100.33M | -945.04M | -851.51M |
| Financing Cash Flow | 355.09M | 1.02B | -105.43M | 184.37M | 505.06M | 1.17B |
Concord Healthcare Group Co., Ltd. Class H Technical Analysis
Concord Healthcare Group Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$380.45M | 11.93 | 4.28% | 7.16% | -2.88% | -22.83% | |
| ― | HK$662.10M | 8.02 | 5.33% | 8.08% | 0.47% | 50.46% | |
| ― | HK$1.62B | 5.59 | 20.47% | 4.41% | -3.56% | -17.45% | |
| ― | HK$400.24M | ― | -8.40% | 2.70% | -21.31% | -149.92% | |
| ― | HK$8.26B | 16.80 | 6.78% | ― | -13.92% | -36.32% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$1.99B | ― | -25.34% | ― | -21.84% | -20.73% |
Concord Healthcare Group Co., Ltd. Class H Corporate Events
Concord Healthcare Group Co., Ltd. announced the release of a pledge of 35.6 million H shares by its controlling shareholder, Beijing Concord. This release follows the fulfillment of obligations under a credit line agreement with SPDB, which had initially required the pledge as a guarantee. The release of the pledge signifies a positive development for Concord Healthcare, potentially enhancing its financial flexibility and market position.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. has announced a financing cooperation with Beijing Daxing Development Finance Leasing Co., Ltd., securing up to RMB20 million for three years at an interest rate of 4.19%. This partnership is expected to expand Concord Healthcare’s financing channels, diversify funding sources, and establish long-term relationships with professional institutions, supporting its future business development.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. has formed a strategic partnership with the Hong Kong and Macau branches of AIA International Limited. This collaboration allows eligible insured members of AIA’s designated group insurance to access affordable cancer proton therapy and health screening packages at the Guangzhou Concord Cancer Center. The partnership aligns with AIA’s strategy to enhance employee wellbeing and marks a significant step in Concord Healthcare’s strategic deployment within the health ecosystem, potentially impacting its market positioning by expanding access to quality healthcare services.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. has announced that its controlling shareholder, Concord Medical Services Holdings Limited (CCM), plans to increase its shareholding in the company over the next twelve months. This move aims to consolidate CCM’s controlling position and demonstrate confidence in the company’s future prospects and long-term development. The shareholding increase will be conducted through CCM’s subsidiaries using its own funds, and specific transactions will be disclosed as per regulatory requirements.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. has announced a significant advancement in artificial intelligence with the development of a self-evolving multimodal intelligent agent system. This system, which is undergoing trial operations, is designed to revolutionize physical examinations by integrating real-time medical knowledge updates and analyzing multimodal data to produce personalized health reports. It aims to reduce diagnostic errors and make high-quality medical resources more accessible, representing a transformative shift in the healthcare industry.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. announced that its controlling shareholder, Beijing Concord Medical Technology Co., Ltd., has pledged 35.6 million H shares, representing nearly all of its direct holdings in the company, to SPDB. This pledge is intended to secure a non-revolving line of credit of up to RMB1.3 billion granted to Guangzhou Hospital, enhancing the company’s financial stability and operational capacity.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
Concord Healthcare Group Co., Ltd. has announced a board meeting scheduled for August 28, 2025, to consider and approve the unaudited financial results for the first half of the year ending June 30, 2025. The meeting will also discuss the potential payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.
Concord Healthcare Group Co., Ltd. has successfully completed the placement of 48,723,600 new H shares under a general mandate, raising approximately HK$258.78 million. The proceeds will be used to fund the construction of Shanghai Concord Medical Cancer Hospital, support the company’s medical AI business, repay loans, and supplement working capital for general corporate purposes.